News Release Details
Surgery Partners, Inc. Announces First Quarter 2017 Results
May 9, 2017
- Revenues increased 7.2% over first quarter 2016 to
$286.2 million - Same-facility revenue increased 7.8% over first quarter 2016 to
$289.6 million - Net loss attributable to
Surgery Partners of$2.8 million improved from$7.19 million in the first quarter 2016 - Adjusted EBITDA increased 4.4% over first quarter 2016 to
$40.1 million - Diluted net loss per share of
$(0.06) vs.$(0.15) in the first quarter 2016
“Surgery Partners recorded solid revenue growth again for the first quarter of 2017,” said
“We believe our model of partnership with independent physicians, physician group practices, health systems and payors offers a superior strategy to deliver value based care. We thank our physicians and staff for their ongoing efforts in this mission.”
As of March 31, 2017, the Company owned or operated 104 surgical facilities primarily in partnership with physicians and, on a select basis, physicians and health systems, in addition to a network of 56 physician practices.
First Quarter 2017 Results
Total revenues for the first quarter of 2017 increased 7.2% to
For the first quarter of 2017, the Company’s net loss attributable to
Liquidity
Full Year 2017 Guidance
For 2017, the Company reiterates the guidance provided on our conference call in March of this year. The Company continues to expect revenue growth of 9% to 11% and Adjusted EBITDA growth in the range of 10% to 15% over 2016.
Conference Call Information
Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company's website at www.surgerypartners.com. The on-line replay will remain available for a limited time beginning immediately following the call.
To learn more about
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, which have been included in reliance of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, involve risks and uncertainties and assumptions relating to our operations, financial condition, business, prospects, growth strategy and liquidity, which may cause our actual results to differ materially from those projected by such forward-looking statements, and the Company cannot give assurances that such statements will prove to be correct. You can identify forward-looking statements because they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “outlook,” “potential,” “project,” “projection,” “plan,” “intend,” “seek,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events.
The forward-looking statements appear in a number of places throughout this press release and include statements regarding our intentions, beliefs or current expectations concerning, among other things, our results of operations, financial condition, liquidity, prospects, growth, strategies and the industry in which we operate. All forward-looking statements are subject to risks and uncertainties, including but not limited to those risks and uncertainties described in “Risk Factors” in our Annual Report on form 10-K for the year ended
The forward-looking statements made in this press release are made only as of the date of the hereof. Except as required by law, we undertake no obligation to update any forward-looking statement, whether as a result of new information or otherwise. More information about potential factors that could affect our business and financial results is included in our filings with the Securities and Exchange Commission.
Use of Non-GAAP Financial Measures
In addition to the results prepared in accordance with generally accepted accounting principles in the United States ("GAAP") provided throughout this press release,
These non-GAAP financial measures are not intended to replace financial performance measures determined in accordance with GAAP. Rather, they are presented as supplemental measures of the Company's performance that management believes may enhance the evaluation of the Company's ongoing operating results. These non-GAAP financial measures are not presented in accordance with GAAP, and the Company’s computation of these non-GAAP financial measures may vary from those used by other companies. These measures have limitations as an analytical tool, and should not be considered in isolation or as a substitute or alternative to net income or loss, operating income or loss, cash flows from operating activities, total indebtedness or any other measures of operating performance, liquidity or indebtedness derived in accordance with GAAP.
About Surgery Partners
Headquartered in
| SURGERY PARTNERS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands, except shares and per share amounts) (Unaudited) |
||||||||
| Three Months Ended March 31, | ||||||||
| 2017 | 2016 | |||||||
| Revenues | $ | 286,183 | $ | 267,074 | ||||
| Operating expenses: | ||||||||
| Salaries and benefits | 89,887 | 86,886 | ||||||
| Supplies | 71,160 | 63,662 | ||||||
| Professional and medical fees | 21,125 | 19,654 | ||||||
| Lease expense | 13,626 | 12,434 | ||||||
| Other operating expenses | 16,150 | 14,067 | ||||||
| Cost of revenues | 211,948 | 196,703 | ||||||
| General and administrative expenses (includes contingent acquisition compensation expense of $2,033 for the quarter ended March 31, 2017) | 15,541 | 12,197 | ||||||
| Depreciation and amortization | 11,108 | 9,568 | ||||||
| Provision for doubtful accounts | 5,675 | 3,873 | ||||||
| Income from equity investments | (1,200 | ) | (758 | ) | ||||
| Loss (gain) on disposal or impairment of long-lived assets, net | 1,196 | (206 | ) | |||||
| Loss on debt refinancing | — | 8,281 | ||||||
| Merger transaction and integration costs | 337 | 3,172 | ||||||
| Electronic health records incentive income | (141 | ) | (93 | ) | ||||
| Other (income) expense | (2 | ) | 57 | |||||
| Total operating expenses | 244,462 | 232,794 | ||||||
| Operating income | 41,721 | 34,280 | ||||||
| Interest expense, net | (25,182 | ) | (22,153 | ) | ||||
| Income before income taxes | 16,539 | 12,127 | ||||||
| Income tax expense | 2,117 | 1,770 | ||||||
| Net income | 14,422 | 10,357 | ||||||
| Less: Net income attributable to non-controlling interests | (17,176 | ) | (17,547 | ) | ||||
| Net loss attributable to Surgery Partners, Inc. | $ | (2,754 | ) | $ | (7,190 | ) | ||
| Net loss per share attributable to common stockholders | ||||||||
| Basic | $ | (0.06 | ) | $ | (0.15 | ) | ||
| Diluted (1) | $ | (0.06 | ) | $ | (0.15 | ) | ||
| Weighted average common shares outstanding | ||||||||
| Basic | 48,019,652 | 48,017,226 | ||||||
| Diluted (1) | 48,019,652 | 48,017,226 | ||||||
| (1) | The impact of potentially dilutive securities for the three months ended March 31, 2017 and 2016 was not considered because the effect would be anti-dilutive in those periods. |
| SURGERY PARTNERS, INC. Unaudited Selected Financial and Operating Data (Amounts in thousands, except shares and per share amounts) |
||||||||
| March 31, 2017 | December 31, 2016 | |||||||
| Balance Sheet Data (at period end): | ||||||||
| Cash and cash equivalents | $ | 55,966 | $ | 69,699 | ||||
| Total current assets | 350,077 | 361,955 | ||||||
| Total assets | 2,289,733 | 2,304,958 | ||||||
| Current maturities of long-term debt | 28,722 | 27,822 | ||||||
| Total current liabilities | 196,456 | 186,725 | ||||||
| Long-term debt, less current maturities | 1,396,042 | 1,414,421 | ||||||
| Total liabilities | 1,790,738 | 1,799,763 | ||||||
| Total Surgery Partners, Inc. stockholders' equity | 8,203 | 9,677 | ||||||
| Non-controlling interests-non-redeemable | 311,403 | 314,997 | ||||||
| Total stockholders' equity | 319,606 | 324,674 | ||||||
| Three Months Ended March 31, | ||||||||
| 2017 | 2016 | |||||||
| Cash Flow Data: | ||||||||
| Net cash provided by (used in): | ||||||||
| Operating activities | $ | 34,870 | $ | 25,244 | ||||
| Investing activities | (6,625 | ) | (18,853 | ) | ||||
| Capital expenditures | (6,350 | ) | (11,804 | ) | ||||
| Investments in new businesses | (275 | ) | (7,049 | ) | ||||
| Financing activities | (41,978 | ) | 70,723 | |||||
| Distributions to non-controlling interests | (19,262 | ) | (17,513 | ) | ||||
| Three Months Ended March 31, | ||||||||
| 2017 | 2016 | |||||||
| Other Data: | ||||||||
| Number of surgical facilities as of the end of period | 104 | 101 | ||||||
| Number of consolidated surgical facilities as of the end of period | 94 | 90 | ||||||
| Cases | 108,829 | 100,756 | ||||||
| Revenue per case | $ | 2,630 | $ | 2,651 | ||||
| Adjusted EBITDA | $ | 40,107 | $ | 38,426 | ||||
| Adjusted EBITDA as a % of revenues | 14.0 | % | 14.4 | % | ||||
| Adjusted EPS- Basic | 0.04 | 0.10 | ||||||
| Adjusted EPS- Diluted | 0.04 | 0.10 | ||||||
| SURGERY PARTNERS, INC. Supplemental Information (Unaudited, in thousands, except cases and growth rates) |
||||||||
| Three Months Ended March 31, | ||||||||
| 2017 | 2016 | |||||||
| Same-facility Information: | ||||||||
| Cases (2) | 107,733 | 105,502 | ||||||
| Case growth | 2.1 | % | N/A | |||||
| Revenue per case (2) | $ | 2,688 | $ | 2,546 | ||||
| Revenue per case growth | 5.6 | % | N/A | |||||
| (2) | Same-facility revenues include revenues from our consolidated and non-consolidated surgical facilities (excluding facilities acquired in new markets or divested during the current and prior periods) along with the revenues from our ancillary services comprised of a diagnostic laboratory, multi-specialty physician practices, urgent care facilities, anesthesia services, optical services and specialty pharmacy services that complement our surgical facilities in our existing markets. |
| Three Months Ended March 31, | ||||||||
| 2017 | 2016 | |||||||
| Segment Revenues: | ||||||||
| Surgical facility services | $ | 258,149 | $ | 245,670 | ||||
| Ancillary services | 25,212 | 17,780 | ||||||
| Optical services | 2,822 | 3,624 | ||||||
| Total revenues | $ | 286,183 | $ | 267,074 | ||||
During 2016, the Company reassessed its segment reporting and realigned the disclosures to reflect the review and decision making made by the Chief Operating Decision Maker (“CODM”). The purpose of these changes was to replace operating income with adjusted EBITDA as the primary profit/loss metric reviewed by the CODM in making key business decisions and on allocation of resources. The Company has revised the segment disclosures below to replace operating income with adjusted EBITDA and has provided a reconciliation from adjusted EBITDA back to net income in the reported consolidated financial information. These changes had no effect on the Company’s reportable segments, which are presented consistent with prior periods.
| Three Months Ended March 31, | ||||||||
| 2017 | 2016 | |||||||
| Segment Adjusted EBITDA: | ||||||||
| Surgical facility services | $ | 48,241 | $ | 45,661 | ||||
| Ancillary services | 3,782 | 3,500 | ||||||
| Optical services | 776 | 879 | ||||||
| Total segment adjusted EBITDA (3) | $ | 52,799 | $ | 50,040 | ||||
| General and administrative expenses | $ | (15,541 | ) | $ | (12,197 | ) | ||
| Non-cash stock compensation expense | 634 | 133 | ||||||
| Contingent acquisition compensation expense | 2,033 | — | ||||||
| Acquisition related costs | 182 | 450 | ||||||
| Total adjusted EBITDA (3) | $ | 40,107 | $ | 38,426 | ||||
| Net income attributable to non-controlling interests | $ | 17,176 | $ | 17,547 | ||||
| Depreciation and amortization | (11,108 | ) | (9,568 | ) | ||||
| Interest and other expense, net | (25,182 | ) | (22,153 | ) | ||||
| Income tax expense | (2,117 | ) | (1,770 | ) | ||||
| Non-cash stock compensation expense | (634 | ) | (133 | ) | ||||
| Contingent acquisition compensation expense | (2,033 | ) | — | |||||
| Merger transaction, integration and practice acquisition costs (4) | (591 | ) | (3,917 | ) | ||||
| Gain on litigation settlement | — | — | ||||||
| (Loss) gain on disposal or impairment of long-lived assets, net | (1,196 | ) | 206 | |||||
| Loss on debt refinancing | — | (8,281 | ) | |||||
| Total net income | $ | 14,422 | $ | 10,357 | ||||
| (3) | The above table reconciles adjusted EBITDA by segment to net income as reflected in the unaudited condensed consolidated statements of operations. |
When we use the term “Adjusted EBITDA,” it is referring to net income minus (a) net income attributable to non-controlling interests plus (b) depreciation and amortization, (c) interest and other expense, net, (d) income tax expense, (e) non-cash stock compensation expense, (f) contingent acquisition compensation expense, (g) merger transaction, integration and practice acquisition costs, (h) (loss) gain on disposal or impairment of long-lived assets and (i) loss on debt refinancing. Non-controlling interests represent the interests of third parties, such as physicians, and in some cases, healthcare systems that own an interest in surgical facilities that we consolidate for financial reporting purposes. Our operating strategy is to apply a market-based approach in structuring its partnerships with individual market dynamics driving the structure. We believe that it is helpful to investors to present Adjusted EBITDA as defined above because it excludes the portion of net income attributable to these third-party interests and clarifies for investors our portion of Adjusted EBITDA generated by our surgical facilities and other operations.
We use Adjusted EBITDA as a measure of liquidity. It is included because we believe that it provides investors with additional information about its ability to incur and service debt and make capital expenditures.
Adjusted EBITDA is not a measurement of financial performance or liquidity under GAAP. It should not be considered in isolation or as a substitute for net income, operating income, cash flows from operating, investing or financing activities, or any other measure calculated in accordance with generally accepted accounting principles. The items excluded from Adjusted EBITDA are significant components in understanding and evaluating financial performance and liquidity. Our calculation of Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies.
| (4) | This amount includes merger transaction and integration costs of $337,000 and $3.2 million for the three months ended March 31, 2017 and 2016, respectively, and practice acquisition costs of $254,000 and $745,000 for the three months ended March 31, 2017 and 2016, respectively. |
SURGERY PARTNERS, INC.
Reconciliation of Non-GAAP Financial Measures
(Unaudited, Amounts in thousands)
From time to time, the Company incurs certain non-recurring gains or losses that are normally nonoperational in nature and that it does not consider relevant in assessing its ongoing operating performance. When significant, Surgery Partners’ management and Board of Directors typically exclude these gains or losses when evaluating the Company’s operating performance and in certain instances when evaluating performance for incentive compensation purposes. Additionally, the Company believes that certain investors and equity analysts exclude these or similar items when evaluating the Company’s current or future operating performance and in making informed investment decisions regarding the Company. Accordingly, the Company provides adjusted net income per share attributable to Surgery Partners, Inc. stockholders as a supplement to its comparable GAAP measure of net income per share attributable to Surgery Partners, Inc. Adjusted net income per share attributable to Surgery Partners, Inc. stockholders should not be considered a measure of financial performance under GAAP, and the items excluded from adjusted net income per share attributable to Surgery Partners, Inc. stockholders are significant components in understanding and assessing financial performance. Adjusted net income per share attributable to Surgery Partners, Inc. stockholders should not be considered in isolation or as an alternative to net income per share attributable to Surgery Partners, Inc. stockholders as presented in the consolidated financial statements.
The following table reconciles net income as reflected in the consolidated statements of operations to adjusted net income used to calculate adjusted net income per share attributable to Surgery Partners, Inc. stockholders:
| Three Months Ended March 31, | ||||||||
| 2017 | 2016 | |||||||
| Consolidated Statements of Operations Data: | ||||||||
| Net Income | $ | 14,422 | $ | 10,357 | ||||
| Less: | ||||||||
| Net income attributable to non-controlling interests | 17,176 | 17,547 | ||||||
| Plus: | ||||||||
| Merger transaction, integration and practice acquisition costs | 591 | 3,917 | ||||||
| Non-cash stock compensation expense | 634 | 133 | ||||||
| Contingent acquisition compensation expense | 2,033 | — | ||||||
| Loss on debt refinancing | — | 8,281 | ||||||
| Loss (gain) on disposal or impairment of long-lived assets, net | 1,196 | (206 | ) | |||||
| Adjusted net income | $ | 1,700 | $ | 4,935 | ||||
| Adjusted net income per share | ||||||||
| Basic | $ | 0.04 | $ | 0.10 | ||||
| Diluted | $ | 0.04 | $ | 0.10 | ||||
| Weighted average common shares outstanding: | ||||||||
| Basic | 48,019,652 | 48,017,226 | ||||||
| Diluted | 48,152,988 | 48,230,151 | ||||||
ContactTeresa Sparks , CFOSurgery Partners, Inc. (615) 234-8940 IR@surgerypartners.com